Home Cart Sign in  
Chemical Structure| 587841-73-4 Chemical Structure| 587841-73-4

Structure of ZCL278
CAS No.: 587841-73-4

Chemical Structure| 587841-73-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ZCL278 is a modulator of Cdc42 through directly binding to Cdc42 with Kd of 11.4 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ZCL278

CAS No. :587841-73-4
Formula : C21H19BrClN5O4S2
M.W : 584.89
SMILES Code : O=C(NC(NC1=CC=C(S(=O)(NC2=NC(C)=CC(C)=N2)=O)C=C1)=S)COC3=CC=C(Br)C=C3Cl
MDL No. :MFCD03623090
InChI Key :XKZDWYDHEBCGCG-UHFFFAOYSA-N
Pubchem ID :1791111

Safety of ZCL278

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of ZCL278

GPCR

Isoform Comparison

Biological Activity

Target
  • Cdc42-subclass

    Cdc42 GTPase, Kd:11.4 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Capan-1 1, 5, and 20 μM 10 minutes To assess the inhibitory effect of ZCL278 on Cdc42 function, results showed that ZCL278 decreased Cdc42 activity in a dose-dependent manner and inhibited microspike formation and stress fibers PMC7162805
PANC-1 1, 5, and 20 μM 10 minutes To assess the inhibitory effect of ZCL278 on Cdc42 function, results showed that ZCL278 decreased Cdc42 activity in a dose-dependent manner and inhibited microspike formation and stress fibers PMC7162805
Swiss 3T3 cells 50 µM 10, 20, 30, 60, 120, 360 minutes ZCL278 at 50 µM formed an initial peak at 10 minutes. ZCL278 then displayed an antagonistic effect at 30 minutes followed by resuming a strong agonistic effect up to 6 hours without showing the plateau PMC11577034
Swiss 3T3 fibroblasts 50 μM 15 min or 1 h Inhibited Cdc42-mediated microspike formation without affecting RhoA-mediated stress fibers PMC3557054
Swiss 3T3 cells 0.01, 0.1, 1, 10, 50, 100 µM 15 minutes ZCL278 promoted Cdc42 activation PMC11577034
Swiss 3T3 cells 50 μM 2 hours Activated Cdc42 and promoted microspike formation PMC6606017
SVG-A cells 50 μM 30 minutes ZCL278 inhibited JUNV infection without affecting cell viability. PMC4836360
Vero cells 50 μM 30 minutes ZCL278 inhibited JUNV infection with an IC50 of ∼14 μM and showed no cytotoxicity. PMC4836360
LNCaP prostate cancer cells 20 μM 48, 96, 144 hours Inhibited cell proliferation PMC6606017
PC3 prostate cancer cells 20 μM 48, 96, 144 hours Inhibited cell proliferation PMC6606017
A549 lung cancer cells 50 μM 48, 96, 144 hours Inhibited cell proliferation PMC6606017
Primary neonatal cortical neurons 50 μM 5 and 10 min Inhibited neuronal branching and growth cone dynamics PMC3557054
PC-3 prostate cancer cells 50 μM 5, 10, and 15 min Inhibited Cdc42 activity and increased Rac/Cdc42 phosphorylation PMC3557054
Human Umbilical Cord Sca-1+ Progenitor Cells (HUCSCs) 10 μM CDC42 inhibitor ZCL278 partially blocked Meox1-mediated enhancement of Sca-1+ progenitor cell migratory capacity PMC8262022
Vascular Smooth Muscle Cells (VSMC) 10 μM CDC42 inhibitor ZCL278 significantly attenuated Meox1 overexpression-induced upregulation of SDF-1α in VSMCs PMC8262022

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice JUNV infection model Intraperitoneal injection 100 μg/g Once daily for 4 days ZCL278 significantly reduced JUNV RNA load in the spleen and showed no toxicity. PMC4836360
3xTg-AD mice Alzheimer's disease model Intraperitoneal injection 20 µg/g Every other day for four weeks ZCL278 ameliorated Alzheimer’s disease-like social behavior PMC11577034
BALB/c-nu mice HCC lung metastasis model Intraperitoneal injection 20 mg/kg Every other day for 28 days To evaluate the inhibitory effect of ZCL278 on HCC lung metastasis PMC9308268

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.71mL

0.34mL

0.17mL

8.55mL

1.71mL

0.85mL

17.10mL

3.42mL

1.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories